Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG 7909-adjuvanted pneumococcal vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
CpG 7909-adjuvanted pneumococcal vaccine is a combination vaccine regimen evaluated by the University of Aarhus for the prevention of pneumococcal disease, particularly in immunocompromised populations such as HIV-infected adults. The regimen utilizes existing pneumococcal vaccines—specifically the 7-valent conjugate vaccine (Prevenar) and the 23-valent polysaccharide vaccine (Pneumo Novum)—administered in conjunction with CpG 7909. CpG 7909 is a synthetic B-class oligodeoxynucleotide that acts as a Toll-like receptor 9 (TLR9) agonist. By targeting TLR9 on B-cells and plasmacytoid dendritic cells, the adjuvant is designed to enhance the magnitude and quality of the immune response to the pneumococcal antigens, potentially overcoming the suboptimal vaccine responses typically observed in HIV-infected individuals.
- Brand names
- PrevenarPneumo NovumVaxImmune
- Other names
- TLR9-adjuvanted pneumococcal vaccineTLR-9-adjuvanted pneumococcal vaccineTLR 9-adjuvanted pneumococcal vaccineCpG 7909 + Prevenar + Pneumo Novum
02
Targets
TLR9 (Toll-like receptor 9)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on CpG 7909-adjuvanted pneumococcal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG 7909-adjuvanted pneumococcal vaccine.